ATNF — 180 Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $1.08bn
- $1.08bn
- 26
- 20
- 84
- 39
Annual cashflow statement for 180 Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.9 | -20.3 | -38.7 | -19.9 | -6.17 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.18 | 9.07 | 24.7 | 11.3 | 3.19 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.73 | -8.2 | 2.72 | -0.014 | 1.73 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.87 | -19.4 | -12.1 | -10.9 | -1.48 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 14.5 | 0 | — | — | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 14.5 | 0 | — | — | — |
| Financing Cash Flow Items | -0.138 | -2.06 | -1.01 | -0.06 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -8.73 | 25.4 | 10.9 | 5.91 | 4.04 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.03 | 6.12 | -1.25 | -4.99 | 2.61 |